Drug checking: how it works around the world

What drug checking is

On-site or lab-based testing that identifies and quantifies substances in drugs supplied by users or collected at events. Methods include reagent (colour) tests, portable spectrometers (FTIR, Raman), gas or liquid chromatography with mass spectrometry (GC-MS, LC-MS), and immunoassays.

Global models and settings

Festival and nightlife services

Widely used in Europe, parts of Australia and New Zealand. Teams often provide on-site testing, harm-reduction counselling and real-time alerts about dangerous batches.

Fixed-site community services

Common in Europe and increasingly in North America. Users submit samples anonymously at harm-reduction centres or pharmacies.

Mobile and outreach units

Vans or pop-up tents bring testing to rural areas, informal gatherings and marginalised populations.

Research and surveillance programs

National monitoring systems (for example wastewater analysis and sentinel sites) track trends and inform public health responses.

Law-enforcement partnerships vs independent models

Some programs operate with police cooperation to prioritise health over prosecution. Others keep strict separation to protect users and encourage uptake.

Regional approaches and policy environments

Europe

Most advanced and widespread. Many countries support testing through public health funding and integrated early-warning systems. Harm-reduction and decriminalisation climates tend to increase acceptance and coverage.

North America

Growing but patchy. Canada and some US cities and provinces have established programs and pilots. Legal barriers and stigma still limit scale in many jurisdictions.

Australia and New Zealand

Strong festival-based services, government-supported research partnerships and robust early-warning networks.

Latin America, Africa and parts of Asia

Emerging initiatives, often led by NGOs and academic groups. Resource constraints and legal risks slow expansion.

Low- and middle-income countries

Testing tends to focus on research, surveillance and targeted harm reduction in urban centres rather than broad public programs.

Benefits demonstrated

Immediate harm reduction

Identifies dangerous adulterants (such as fentanyl, synthetic opioids and novel psychoactive substances) and reduces overdose risk through user education and alerts.

Public health surveillance

Detects new substances and informs treatment, policy and law enforcement.

Behavioural change

Many users change what they do (discard, reduce the dose or avoid) when told about unexpected or high-potency contents.

Policy impact

Testing data supports evidence-based drug policy, targeted interventions and resource allocation.

Limitations and challenges

Technical limits

Field methods may miss low-concentration adulterants or novel analogues, so confirmatory lab tests are often needed.

Legal and regulatory barriers

Possessing illicit substances for testing can expose users and providers to prosecution in some countries.

Resources and scalability

High-quality analytical equipment and trained staff are costly. Services often rely on short-term funding or volunteers.

Trust and engagement

Stigma, criminalisation and privacy concerns reduce uptake, especially among marginalised groups.

Speed vs accuracy

Rapid on-site tests give quick results but have higher detection limits than lab-based methods.

Best practices and trends

Combined models

Pair rapid on-site screening with confirmatory lab analysis for full coverage.

Anonymous, low-threshold access

Protects users and increases participation.

Strong early-warning networks

Rapid data sharing between sites, public health agencies and communities saves lives.

Integration with broader services

Link testing to naloxone distribution, clinical care, mental health support and safer-use advice.

Technological advances

Portable spectrometers are becoming more affordable and easier to use, and digital reporting tools improve surveillance.

Community-led and peer-based delivery

Peers increase trust and cultural competence, which improves reach.

Outlook

Expansion is likely where legal reforms, public funding and evidence-based drug policies advance. Continued technical improvements and data integration will strengthen surveillance and prevention. Scaling services worldwide depends on addressing legal obstacles, securing sustainable funding, and centring user trust and privacy.